Αποτελέσματα Αναζήτησης
14 Δεκ 2023 · This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
- Cameron D, Piccart-Gebhart Mj, Gelber Rd, Et Al. 11 Years' Follow-Up of Trastuzumab After Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of The HERceptin Adjuvant (Hera) Trial. Lancet 2017; 389:1195
After a median follow-up of 11 years (IQR 10·09-11·53),...
- Martin M, Holmes Fa, Ejlertsen B, Et Al. Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol 2017; 18:1688
In the cohort of patients with node-negative disease, the...
- Curigliano G, Viale G, Bagnardi V, Et Al. Clinical Relevance of Her2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. J Clin Oncol 2009; 27:5693
This site uses cookies. By continuing to browse this site...
- Bowles Ej, Wellman R, Feigelson Hs, Et Al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: a Retrospective Cohort Study. J Natl Cancer Inst 2012; 104:1293
METHODS We conducted a population-based, retrospective...
- Joensuu H, Kellokumpu-Lehtinen Pl, Bono P, Et Al. Adjuvant Docetaxel Or Vinorelbine With Or Without Trastuzumab for Breast Cancer. N Engl J Med 2006; 354:809
8 PubMed | TI Adjuvant docetaxel or vinorelbine with or...
- Noone Am, Cronin Ka, Altekruse Sf, Et Al. Cancer Incidence and Survival Trends by Subtype Using Data From The Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev 2017; 26:632
1 PubMed | TI Cancer Incidence and Survival Trends by...
- Earl Hm, Hiller L, Vallier Al, Et Al. 6 Versus 12 Months of Adjuvant Trastuzumab for HER2-positive Early Breast Cancer (Persephone): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial. Lancet 2019; 393:2599
We randomly assigned patients with HER2-positive early...
- Pivot X, Gligorov J, Müller V, Et Al. Preference for Subcutaneous Or Intravenous Administration of Trastuzumab in Patients With HER2-positive Early Breast Cancer (PrefHer): an Open-Label Randomised Study. Lancet Oncol 2013; 14:962
This site uses cookies. By continuing to browse this site...
- Cameron D, Piccart-Gebhart Mj, Gelber Rd, Et Al. 11 Years' Follow-Up of Trastuzumab After Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of The HERceptin Adjuvant (Hera) Trial. Lancet 2017; 389:1195
20 Οκτ 2020 · The aim of this work is to update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.
20 Σεπ 2024 · This clinical insights article is derived from recommendations in Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
AC chemotherapy works by stopping the cancer cells from dividing and multiplying, which blocks the growth of the cancer. Different chemotherapy drugs attack cancer cells at different stages of their growth.
This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
1 Μαΐ 2018 · Dose-Dense AC + TH is often given with the goal of cure and administered either before surgery (neoadjuvant therapy) to shrink the size of the tumor, or after surgery (adjuvant therapy) to kill any cancer cells that may be still present in the body.
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
